Biodexa Pharmaceuticals annual current ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Current Ratio Growth & History (BDRX)
Biodexa Pharmaceuticals's current ratio was 2.03 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.03 | 0.28 | +16.00% |
| 2024 | 2024-12-31 | 1.75 | 0.49 | +38.64% |
| 2023 | 2023-12-31 | 1.26 | −1.21 | −48.84% |
| 2022 | 2022-12-31 | 2.47 | −3.92 | −61.38% |
| 2021 | 2021-12-31 | 6.39 | 3.29 | +105.87% |
| 2020 | 2020-12-31 | 3.10 | 0.68 | +28.01% |
| 2019 | 2019-12-31 | 2.42 | 0.15 | +6.62% |
| 2018 | 2018-12-31 | 2.27 | 0.05 | +2.32% |
| 2017 | 2017-12-31 | 2.22 | −0.16 | −6.90% |
| 2016 | 2016-12-31 | 2.39 | 0.15 | +6.81% |
| 2015 | 2015-12-31 | 2.23 | — | — |
Biodexa Pharmaceuticals quarterly current ratio
Q4.18
Q4.19
Q4.20
Q4.21
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 2.03 | 0.28 | +16.00% |
| Q2 2025 | 2025-06-30 | 3.63 | 1.47 | +67.82% |
| Q4 2024 | 2024-12-31 | 1.75 | 0.49 | +38.64% |
| Q2 2024 | 2024-06-30 | 2.16 | −1.02 | −32.07% |
| Q4 2023 | 2023-12-31 | 1.26 | −1.21 | −48.84% |
| Q2 2023 | 2023-06-30 | 3.18 | — | — |
| Q4 2022 | 2022-12-31 | 2.47 | −3.92 | −61.38% |
| Q4 2021 | 2021-12-31 | 6.39 | 3.29 | +105.87% |
| Q4 2020 | 2020-12-31 | 3.10 | 0.68 | +28.01% |
| Q4 2019 | 2019-12-31 | 2.42 | 0.15 | +6.62% |
| Q4 2018 | 2018-12-31 | 2.27 | — | — |
Biodexa Pharmaceuticals current ratio trends
Over the last five fiscal years, Biodexa Pharmaceuticals's current ratio decreased from 3.10 to 2.03, a change of −1.07. The latest reported quarter, Q4 2025, shows 2.03.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...